Skip to content

Research on individualized treatment of pancreatic cancer patients based on organoid model

Research on individualized treatment of pancreatic cancer patients based on organoid model

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037214
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Have undergone radical resection of pancreatic cancer; 2. No serious underlying diseases; 3. Have not undergone radiotherapy or chemotherapy before; 4. Pathologically diagnosed as pancreatic cancer; 5. No significant disfunction of heart, lung, or kidney and no HIV or syphilis infection; 6. All patients should sign an informed consent form when selected.

Exclusion criteria

Exclusion criteria: 1. The general condition of pancreatic cancer patients before surgery is poor, and it is estimated that they cannot tolerate surgery, postoperative chemotherapy and targeted therapy; 2. Patients with metastases; 3. Patients with unstable angina, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, prolonged QT interval (>450ms); 4. Malignant tumors in other parts appeared within the last 5 years; 5. The patient cannot be followed up or is participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Genomics;

Countries

China

Contacts

Public ContactGang Jin

Shanghai Changhai Hospital

jingang@sohu.com+86 21-31161628

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026